Onconetix, Inc. (ONCO)
NASDAQ: ONCO · IEX Real-Time Price · USD
+0.019 (14.61%)
May 22, 2024, 4:00 PM EDT - Market closed

Company Description

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology.

It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.

The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.

Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Onconetix, Inc.
Onconetix logo
Country United States
Founded 2018
IPO Date Feb 18, 2022
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Dr. Ralph Schiess Ph.D.

Contact Details

201 E. Fifth Street, Suite 1900
Cincinnati, Ohio 45202
United States
Phone 513-620-4101
Website onconetix.gcs-web.com

Stock Details

Ticker Symbol ONCO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $9.00
CIK Code 0001782107
CUSIP Number 682160106
ISIN Number US09610B1089
SIC Code 2834

Key Executives

Name Position
Dr. Ralph Schiess Ph.D. Interim Chief Executive Officer and Chief Science Officer
Bruce Harmon Chief Financial Officer
Dr. Brian Price Ph.D. Head of Technology Strategy
Frank A. Jaeger M.A., M.B.A. Senior Vice President of Marketing and Business Development
Andrew D. Skibo Ph.D. Global Head of Biologics Operations
Theodore Scott Yoho Head of Business Development
Dr. Ali I. Fattom Ph.D. Head of Science and Discovery
Dr. Jay Newmark M.B.A., M.D. Chief Medical Officer
Christian Bruhlmann Chief Strategy Officer and GM of Europe
Dr. Donald L. Very Jr., Ph.D. Senior Vice President of Commercial Research and Development

Latest SEC Filings

Date Type Title
May 20, 2024 10-Q Quarterly Report
May 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
May 13, 2024 8-K Current Report
Apr 26, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 26, 2024 8-K Current Report
Apr 11, 2024 10-K Annual Report
Apr 8, 2024 8-K Current Report
Apr 1, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 13, 2024 8-K/A [Amend] Current report
Feb 27, 2024 8-K/A [Amend] Current report